Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Parisi

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experienceMassimiliano Salati, Eleonora Borghi, Riccardo Cuoghi Costantini, et al.
Frontiers in Oncology|January 7, 2022
The Role of Electrochemotherapy in the Cutaneous and Subcutaneous Metastases From Breast Cancer: Analysis of Predictive Factors to Treatment From an Italian Cohort of PatientsFrancesco Russano, Paolo Del Fiore, Claudia Di Prata, et al.
Cancers|January 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control StudyMargherita Turinetto, Andrea Ricotti, Claudia Marchetti, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2019
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyAlessandro Parisi, Alessio Cortellini, Michela Roberto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 22, 2025
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDYGerardo Rosati, Alfonso De Stefano, Angelo Restivo, et al.
Cancers|June 24, 2022
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational StatusAzzurra Irelli, Alessandro Parisi, Carla D'Orazio, et al.
NPJ Breast Cancer|February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Frontiers in Oncology|September 1, 2022
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup StudyRiccardo Marconcini, Paolo Fava, Amedeo Nuzzo, et al.
International Journal of Colorectal Disease|May 9, 2020
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the differenceMichela Roberto, Paolo Marchetti, Giulia Arrivi, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experienceMassimiliano Salati, Eleonora Borghi, Riccardo Cuoghi Costantini, et al.
Frontiers in Oncology|January 7, 2022
The Role of Electrochemotherapy in the Cutaneous and Subcutaneous Metastases From Breast Cancer: Analysis of Predictive Factors to Treatment From an Italian Cohort of PatientsFrancesco Russano, Paolo Del Fiore, Claudia Di Prata, et al.
Cancers|January 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control StudyMargherita Turinetto, Andrea Ricotti, Claudia Marchetti, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2019
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyAlessandro Parisi, Alessio Cortellini, Michela Roberto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 22, 2025
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDYGerardo Rosati, Alfonso De Stefano, Angelo Restivo, et al.
Cancers|June 24, 2022
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational StatusAzzurra Irelli, Alessandro Parisi, Carla D'Orazio, et al.
NPJ Breast Cancer|February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Frontiers in Oncology|September 1, 2022
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup StudyRiccardo Marconcini, Paolo Fava, Amedeo Nuzzo, et al.
International Journal of Colorectal Disease|May 9, 2020
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the differenceMichela Roberto, Paolo Marchetti, Giulia Arrivi, et al.
Pageof 11